-
(
AmaralT
OsewoldM
PresserD
, et al. Advanced cutaneous squamous
cell carcinoma: real world data of patient profiles and treatment
patterns. J Eur Acad Dermatol Venereol
2019; 33(Suppl. 8):
44–51.31658392)
AmaralT
OsewoldM
PresserD
, et al. Advanced cutaneous squamous
cell carcinoma: real world data of patient profiles and treatment
patterns. J Eur Acad Dermatol Venereol
2019; 33(Suppl. 8):
44–51.31658392
AmaralT
OsewoldM
PresserD
, et al. Advanced cutaneous squamous
cell carcinoma: real world data of patient profiles and treatment
patterns. J Eur Acad Dermatol Venereol
2019; 33(Suppl. 8):
44–51.31658392,
AmaralT
OsewoldM
PresserD
, et al. Advanced cutaneous squamous
cell carcinoma: real world data of patient profiles and treatment
patterns. J Eur Acad Dermatol Venereol
2019; 33(Suppl. 8):
44–51.31658392
-
A first-in-human study of repeat dosing with REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), as single therapy and in combination with other anti-cancer therapies in patients with advanced malignancies
-
N.
Gross,
R.
Ferrarotto,
P.
Nagarajan,
D.
Bell,
A.
El-Naggar,
Jason
Johnson,
Ying
Yuan,
B.
Glisson,
M.
Wong,
D.
Rosenthal,
B.
Esmaeli,
M.
Migden,
J.
Wargo,
R.
Weber,
J.
Myers
(2019)
Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
Annals of Oncology
-
M.
Migden,
D.
Rischin,
C.
Schmults,
A.
Guminski,
A.
Hauschild,
K.
Lewis,
C.
Chung,
L.
Hernandez-Aya,
A.
Lim,
A.
Chang,
G.
Rabinowits,
A.
Thai,
L.
Dunn,
B.
Hughes,
N.
Khushalani,
B.
Modi,
D.
Schadendorf,
Bo
Gao,
F.
Seebach,
Siyu
Li,
Jingjin
Li,
M.
Mathias,
J.
Booth,
K.
Mohan,
E.
Stankevich,
H.
Babiker,
I.
Braña,
M.
Gil-Martin,
J.
Homsi,
M.
Johnson,
V.
Moreno,
J.
Niu,
T.
Owonikoko,
K.
Papadopoulos,
G.
Yancopoulos,
I.
Lowy,
M.
Fury
(2018)
PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma
The New England Journal of Medicine, 379
-
A.
Goodman,
S.
Kato,
L.
Bazhenova,
S.
Patel,
G.
Frampton,
V.
Miller,
P.
Stephens,
G.
Daniels,
R.
Kurzrock
(2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Molecular Cancer Therapeutics, 16
-
(
BrierleyJD
GospodarowiczMK
WittekindC
. TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
Wiley-Blackwell,
2017.)
BrierleyJD
GospodarowiczMK
WittekindC
. TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
Wiley-Blackwell,
2017.
BrierleyJD
GospodarowiczMK
WittekindC
. TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
Wiley-Blackwell,
2017.,
BrierleyJD
GospodarowiczMK
WittekindC
. TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
Wiley-Blackwell,
2017.
-
(
Regeneron Pharmaceuticals. A first-in-human
study of repeat dosing with REGN2810, a monoclonal, fully human antibody to
programmed death-1 (PD-1), as single therapy and in combination with other
anti-cancer therapies in patients with advanced malignancies
(ClinicalTrials.gov record: NCT02383212), https://clinicaltrials.gov/ct2/show/NCT02383212
(2015, accessed 27 July
2020).)
Regeneron Pharmaceuticals. A first-in-human
study of repeat dosing with REGN2810, a monoclonal, fully human antibody to
programmed death-1 (PD-1), as single therapy and in combination with other
anti-cancer therapies in patients with advanced malignancies
(ClinicalTrials.gov record: NCT02383212), https://clinicaltrials.gov/ct2/show/NCT02383212
(2015, accessed 27 July
2020).
Regeneron Pharmaceuticals. A first-in-human
study of repeat dosing with REGN2810, a monoclonal, fully human antibody to
programmed death-1 (PD-1), as single therapy and in combination with other
anti-cancer therapies in patients with advanced malignancies
(ClinicalTrials.gov record: NCT02383212), https://clinicaltrials.gov/ct2/show/NCT02383212
(2015, accessed 27 July
2020).,
Regeneron Pharmaceuticals. A first-in-human
study of repeat dosing with REGN2810, a monoclonal, fully human antibody to
programmed death-1 (PD-1), as single therapy and in combination with other
anti-cancer therapies in patients with advanced malignancies
(ClinicalTrials.gov record: NCT02383212), https://clinicaltrials.gov/ct2/show/NCT02383212
(2015, accessed 27 July
2020).
-
(
RischinD
KhushalaniNI
SchmultsCD
, et al. Phase 2 study of cemiplimab
in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer
follow-up. J Clin Oncol
2020; 38: 10018.)
RischinD
KhushalaniNI
SchmultsCD
, et al. Phase 2 study of cemiplimab
in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer
follow-up. J Clin Oncol
2020; 38: 10018.
RischinD
KhushalaniNI
SchmultsCD
, et al. Phase 2 study of cemiplimab
in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer
follow-up. J Clin Oncol
2020; 38: 10018.,
RischinD
KhushalaniNI
SchmultsCD
, et al. Phase 2 study of cemiplimab
in patients with advanced cutaneous squamous cell carcinoma (CSCC): longer
follow-up. J Clin Oncol
2020; 38: 10018.
-
(
VenablesZC
AutierP
NijstenT
, et al. Nationwide incidence of
metastatic cutaneous squamous cell carcinoma in England.
JAMA Dermatol
2019; 155:
298–306.30484823)
VenablesZC
AutierP
NijstenT
, et al. Nationwide incidence of
metastatic cutaneous squamous cell carcinoma in England.
JAMA Dermatol
2019; 155:
298–306.30484823
VenablesZC
AutierP
NijstenT
, et al. Nationwide incidence of
metastatic cutaneous squamous cell carcinoma in England.
JAMA Dermatol
2019; 155:
298–306.30484823,
VenablesZC
AutierP
NijstenT
, et al. Nationwide incidence of
metastatic cutaneous squamous cell carcinoma in England.
JAMA Dermatol
2019; 155:
298–306.30484823
-
(
Jambusaria-PahlajaniA
KanetskyPA
KariaPS
, et al. Evaluation of AJCC tumor
staging for cutaneous squamous cell carcinoma and a proposed alternative
tumor staging system. JAMA Dermatol
2013; 149:
402–410.23325457)
Jambusaria-PahlajaniA
KanetskyPA
KariaPS
, et al. Evaluation of AJCC tumor
staging for cutaneous squamous cell carcinoma and a proposed alternative
tumor staging system. JAMA Dermatol
2013; 149:
402–410.23325457
Jambusaria-PahlajaniA
KanetskyPA
KariaPS
, et al. Evaluation of AJCC tumor
staging for cutaneous squamous cell carcinoma and a proposed alternative
tumor staging system. JAMA Dermatol
2013; 149:
402–410.23325457,
Jambusaria-PahlajaniA
KanetskyPA
KariaPS
, et al. Evaluation of AJCC tumor
staging for cutaneous squamous cell carcinoma and a proposed alternative
tumor staging system. JAMA Dermatol
2013; 149:
402–410.23325457
-
T.
Nelson,
R.
Ashton
(2017)
Low incidence of metastasis and recurrence from cutaneous squamous cell carcinoma found in a UK population: Do we need to adjust our thinking on this rare but potentially fatal event?
Journal of Surgical Oncology, 116
-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): squamous cell skin cancer NCCN evidence blocks, version 2.2020
-
U.
Hillen,
U.
Leiter,
S.
Haase,
R.
Kaufmann,
J.
Becker,
R.
Gutzmer,
P.
Terheyden,
A.
Krause‐Bergmann,
H.
Schulze,
J.
Hassel,
N.
Lahner,
U.
Wollina,
F.
Ziller,
J.
Utikal,
C.
Hafner,
J.
Ulrich,
H.
Machens,
C.
Weishaupt,
A.
Hauschild,
P.
Mohr,
C.
Pföhler,
J.
Maurer,
P.
Wolff,
C.
Windemuth-Kieselbach,
D.
Schadendorf,
E.
Livingstone
(2018)
Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.
European journal of cancer, 96
-
(1940)
The Background of Structure and Function
British Medical Journal, 1
-
K.
Peris,
M.
Alaibac,
G.
Argenziano,
A.
Stefani,
M.
Fargnoli,
P.
Frascione,
G.
Gualdi,
C.
Longo,
E.
Moscarella,
L.
Naldi,
G.
Pellacani,
N.
Pimpinelli,
P.
Quaglino,
M.
Salgarello,
P.
Sollena,
V.
Valentini,
I.
Zalaudek,
P.
Calzavara-Pinton
(2018)
Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines.
Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 153 6
-
A.
Stratigos,
C.
Garbe,
C.
Dessinioti,
C.
Lebbé,
V.
Bataille,
L.
Bastholt,
B.
Dréno,
M.
Fargnoli,
A.
Forsea,
C.
Frenard,
C.
Harwood,
A.
Hauschild,
C.
Hoeller,
L.
Kandolf-Sekulovic,
R.
Kaufmann,
N.
Kelleners-Smeets,
J.
Malvehy,
V.
Marmol,
M.
Middleton,
D.
Moreno-Ramírez,
Giovanni
Pellecani,
K.
Peris,
P.
Saiag,
M.
Everdingen,
R.
Vieira,
I.
Zalaudek,
A.
Eggermont,
J.
Grob
(2020)
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention.
European journal of cancer
-
M.
Stevenson,
Claire
Wang,
M.
Abikhair,
N.
Roudiani,
D.
Felsen,
J.
Krueger,
A.
Pavlick,
J.
Carucci
(2017)
Expression of Programmed Cell Death Ligand in Cutaneous Squamous Cell Carcinoma and Treatment of Locally Advanced Disease With Pembrolizumab
JAMA Dermatology, 153
-
(
SouraE
GagariE
StratigosA
. Advanced cutaneous squamous cell carcinoma: how
is it defined and what new therapeutic approaches are
available?
Curr Opin Oncol
2019; 31:
461–468.31394558)
SouraE
GagariE
StratigosA
. Advanced cutaneous squamous cell carcinoma: how
is it defined and what new therapeutic approaches are
available?
Curr Opin Oncol
2019; 31:
461–468.31394558
SouraE
GagariE
StratigosA
. Advanced cutaneous squamous cell carcinoma: how
is it defined and what new therapeutic approaches are
available?
Curr Opin Oncol
2019; 31:
461–468.31394558,
SouraE
GagariE
StratigosA
. Advanced cutaneous squamous cell carcinoma: how
is it defined and what new therapeutic approaches are
available?
Curr Opin Oncol
2019; 31:
461–468.31394558
-
(
ThompsonAK
KelleyBF
ProkopLJ
, et al. Risk factors for cutaneous
squamous cell carcinoma recurrence, metastasis, and disease-specific death:
a systematic review and meta-analysis. JAMA
Dermatol
2016; 152:
419–428.26762219)
ThompsonAK
KelleyBF
ProkopLJ
, et al. Risk factors for cutaneous
squamous cell carcinoma recurrence, metastasis, and disease-specific death:
a systematic review and meta-analysis. JAMA
Dermatol
2016; 152:
419–428.26762219
ThompsonAK
KelleyBF
ProkopLJ
, et al. Risk factors for cutaneous
squamous cell carcinoma recurrence, metastasis, and disease-specific death:
a systematic review and meta-analysis. JAMA
Dermatol
2016; 152:
419–428.26762219,
ThompsonAK
KelleyBF
ProkopLJ
, et al. Risk factors for cutaneous
squamous cell carcinoma recurrence, metastasis, and disease-specific death:
a systematic review and meta-analysis. JAMA
Dermatol
2016; 152:
419–428.26762219
-
A.
Jarkowski,
R.
Hare,
P.
Loud,
J.
Skitzki,
J.
Kane,
K.
May,
N.
Zeitouni,
Jill
Nestico,
Karen
Vona,
A.
Groman,
N.
Khushalani
(2016)
Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature
American Journal of Clinical Oncology, 39
-
(
European Medicines Agency. Libtayo (cemiplimab):
EPAR – product information, https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo#product-information-section
(2019, accessed 27 July
2020).)
European Medicines Agency. Libtayo (cemiplimab):
EPAR – product information, https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo#product-information-section
(2019, accessed 27 July
2020).
European Medicines Agency. Libtayo (cemiplimab):
EPAR – product information, https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo#product-information-section
(2019, accessed 27 July
2020).,
European Medicines Agency. Libtayo (cemiplimab):
EPAR – product information, https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo#product-information-section
(2019, accessed 27 July
2020).
-
D.
Rischin,
N.
Khushalani,
C.
Schmults,
A.
Guminski,
A.
Chang,
K.
Lewis,
A.
Lim,
L.
Hernandez-Aya,
B.
Hughes,
D.
Schadendorf,
A.
Hauschild,
A.
Thai,
E.
Stankevich,
J.
Booth,
S.
Yoo,
Siyu
Li,
Zhen
Chen,
E.
Okoye,
Chieh-I.
Chen,
V.
Mastey,
M.
Sasane,
I.
Lowy,
M.
Fury,
M.
Migden
(2021)
Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Journal for Immunotherapy of Cancer, 9
-
(
BüttnerR
LongshoreJW
López-RíosF
, et al. Implementing TMB measurement
in clinical practice: considerations on assay requirements.
ESMO Open
2019; 4: e000442.)
BüttnerR
LongshoreJW
López-RíosF
, et al. Implementing TMB measurement
in clinical practice: considerations on assay requirements.
ESMO Open
2019; 4: e000442.
BüttnerR
LongshoreJW
López-RíosF
, et al. Implementing TMB measurement
in clinical practice: considerations on assay requirements.
ESMO Open
2019; 4: e000442.,
BüttnerR
LongshoreJW
López-RíosF
, et al. Implementing TMB measurement
in clinical practice: considerations on assay requirements.
ESMO Open
2019; 4: e000442.
-
D.
Rischin,
N.
Khushalani,
C.
Schmults,
A.
Guminski,
A.
Chang,
K.
Lewis,
A.
Lim,
L.
Hernandez-Aya,
B.
Hughes,
D.
Schadendorf,
A.
Hauschild,
E.
Stankevich,
J.
Booth,
S.
Yoo,
Zhen
Chen,
E.
Okoye,
I.
Lowy,
M.
Fury,
M.
Migden
(2020)
Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up
, 4
-
G.
Brancaccio,
G.
Briatico,
C.
Pellegrini,
T.
Rocco,
E.
Moscarella,
M.
Fargnoli
(2021)
Risk Factors and Diagnosis of Advanced Cutaneous Squamous Cell Carcinoma
Dermatology Practical & Conceptual, 11
-
R.
Büttner,
J.
Longshore,
F.
López-Rios,
S.
Merkelbach-Bruse,
N.
Normanno,
E.
Rouleau,
F.
Penault-Llorca
(2019)
Implementing TMB measurement in clinical practice: considerations on assay requirements
ESMO Open, 4
-
(
BrancaccioG
FargnoliMC
BriaticoG
, et al. Risk factors and diagnosis
of advanced cutaneous squamous cell carcinoma.
Dermatol Pract Concept
2021; 11: e2021166S.)
BrancaccioG
FargnoliMC
BriaticoG
, et al. Risk factors and diagnosis
of advanced cutaneous squamous cell carcinoma.
Dermatol Pract Concept
2021; 11: e2021166S.
BrancaccioG
FargnoliMC
BriaticoG
, et al. Risk factors and diagnosis
of advanced cutaneous squamous cell carcinoma.
Dermatol Pract Concept
2021; 11: e2021166S.,
BrancaccioG
FargnoliMC
BriaticoG
, et al. Risk factors and diagnosis
of advanced cutaneous squamous cell carcinoma.
Dermatol Pract Concept
2021; 11: e2021166S.
-
D.
Rischin,
M.
Migden,
A.
Lim,
C.
Schmults,
N.
Khushalani,
B.
Hughes,
D.
Schadendorf,
L.
Dunn,
L.
Hernandez-Aya,
A.
Chang,
B.
Modi,
A.
Hauschild,
C.
Ulrich,
T.
Eigentler,
Brian
Stein,
A.
Pavlick,
J.
Geiger,
R.
Gutzmer,
Murad
Alam,
E.
Okoye,
M.
Mathias,
V.
Janković,
E.
Stankevich,
J.
Booth,
Siyu
Li,
I.
Lowy,
M.
Fury,
A.
Guminski
(2020)
Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing
Journal for Immunotherapy of Cancer, 8
-
H.
Montaudié,
J.
Viotti,
P.
Combemale,
C.
Dutriaux,
N.
Dupin,
C.
Robert,
L.
Mortier,
R.
Kaphan,
A.
Duval-Modeste,
S.
Dalle,
J.
Quatrebarbes,
A.
Stefan,
F.
Brunet‐Possenti,
Maria
Kogay,
Alexandra
Picard‐Gauci,
G.
Poissonnet,
F.
Peyrade
(2020)
Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study
Oncotarget, 11
-
K.
Brantsch,
C.
Meisner,
B.
Schönfisch,
B.
Trilling,
J.
Wehner-Caroli,
M.
Röcken,
H.
Breuninger
(2008)
Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.
The Lancet. Oncology, 9 8
-
J.
Kim,
Jeffrey
Kozlow,
B.
Mittal,
J.
Moyer,
Thomas
Olenecki,
P.
Rodgers
(2018)
Guidelines of care for the management of cutaneous squamous cell carcinoma.
Journal of the American Academy of Dermatology, 78 3
-
A.
Jambusaria-Pahlajani,
P.
Kanetsky,
P.
Karia,
W.
Hwang,
J.
Gelfand,
F.
Whalen,
R.
Elenitsas,
Xiaowei
Xu,
C.
Schmults
(2013)
Evaluation of AJCC tumor staging for cutaneous squamous cell carcinoma and a proposed alternative tumor staging system.
JAMA dermatology, 149 4
-
(
National Institute of Health and Care Excellence.
Cemiplimab for treating metastatic or locally advanced
cutaneous squamous cell carcinoma. Technology appraisal guidance
[TA592], https://www.nice.org.uk/guidance/TA592 (2019,
accessed 11 August 2020).)
National Institute of Health and Care Excellence.
Cemiplimab for treating metastatic or locally advanced
cutaneous squamous cell carcinoma. Technology appraisal guidance
[TA592], https://www.nice.org.uk/guidance/TA592 (2019,
accessed 11 August 2020).
National Institute of Health and Care Excellence.
Cemiplimab for treating metastatic or locally advanced
cutaneous squamous cell carcinoma. Technology appraisal guidance
[TA592], https://www.nice.org.uk/guidance/TA592 (2019,
accessed 11 August 2020).,
National Institute of Health and Care Excellence.
Cemiplimab for treating metastatic or locally advanced
cutaneous squamous cell carcinoma. Technology appraisal guidance
[TA592], https://www.nice.org.uk/guidance/TA592 (2019,
accessed 11 August 2020).
-
R.
Samstein,
Chung-Han
Lee,
A.
Shoushtari,
M.
Hellmann,
R.
Shen,
Y.
Janjigian,
D.
Barron,
A.
Zehir,
E.
Jordan,
A.
Omuro,
T.
Kaley,
S.
Kendall,
R.
Motzer,
A.
Hakimi,
M.
Voss,
P.
Russo,
J.
Rosenberg,
G.
Iyer,
B.
Bochner,
D.
Bajorin,
H.
Al-Ahmadie,
J.
Chaft,
C.
Rudin,
Gregory
Riely,
S.
Baxi,
A.
Ho,
R.
Wong,
D.
Pfister,
J.
Wolchok,
C.
Barker,
P.
Gutin,
C.
Brennan,
V.
Tabar,
I.
Mellinghoff,
L.
Deangelis,
C.
Ariyan,
N.
Lee,
W.
Tap,
M.
Gounder,
S.
D’Angelo,
L.
Saltz,
Z.
Stadler,
H.
Scher,
J.
Baselga,
P.
Razavi,
C.
Klebanoff,
R.
Yaeger,
N.
Segal,
G.
Ku,
R.
DeMatteo,
M.
Ladanyi,
N.
Rizvi,
M.
Berger,
N.
Riaz,
D.
Solit,
T.
Chan,
L.
Morris
(2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Nature Genetics, 51
-
(
US Food and Drug Administration. Libtayo
(cemiplimab-rwlc) injection, for intravenous use: highlights of prescribing
information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf
(2018, accessed 27 July
2020).)
US Food and Drug Administration. Libtayo
(cemiplimab-rwlc) injection, for intravenous use: highlights of prescribing
information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf
(2018, accessed 27 July
2020).
US Food and Drug Administration. Libtayo
(cemiplimab-rwlc) injection, for intravenous use: highlights of prescribing
information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf
(2018, accessed 27 July
2020).,
US Food and Drug Administration. Libtayo
(cemiplimab-rwlc) injection, for intravenous use: highlights of prescribing
information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf
(2018, accessed 27 July
2020).
-
S.
Topalian,
C.
Drake,
D.
Pardoll
(2015)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Cancer cell, 27 4
-
J.
Cooper
(1997)
Ajcc Cancer Staging Manual
-
Ch.
Wittekind,
M.
Gospodarowicz,
L.
Sobin
(2009)
TNM Classification of Malignant Tumours, 7th Edition
-
(
MontaudiéH
ViottiJ
CombemaleP
, et al. Cetuximab is efficient and
safe in patients with advanced cutaneous squamous cell carcinoma: a
retrospective, multicentre study.
Oncotarget
2020; 11:
378–385.32064041)
MontaudiéH
ViottiJ
CombemaleP
, et al. Cetuximab is efficient and
safe in patients with advanced cutaneous squamous cell carcinoma: a
retrospective, multicentre study.
Oncotarget
2020; 11:
378–385.32064041
MontaudiéH
ViottiJ
CombemaleP
, et al. Cetuximab is efficient and
safe in patients with advanced cutaneous squamous cell carcinoma: a
retrospective, multicentre study.
Oncotarget
2020; 11:
378–385.32064041,
MontaudiéH
ViottiJ
CombemaleP
, et al. Cetuximab is efficient and
safe in patients with advanced cutaneous squamous cell carcinoma: a
retrospective, multicentre study.
Oncotarget
2020; 11:
378–385.32064041
-
C.
Schmults,
P.
Karia,
J.
Carter,
Jiali
Han,
A.
Qureshi
(2013)
Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study.
JAMA dermatology, 149 5
-
(
MigdenMR
KhushalaniNI
ChangALS
, et al. Cemiplimab in locally
advanced cutaneous squamous cell carcinoma: results from an open-label,
phase 2, single-arm trial. Lancet Oncol
2020; 21:
294–305.31952975)
MigdenMR
KhushalaniNI
ChangALS
, et al. Cemiplimab in locally
advanced cutaneous squamous cell carcinoma: results from an open-label,
phase 2, single-arm trial. Lancet Oncol
2020; 21:
294–305.31952975
MigdenMR
KhushalaniNI
ChangALS
, et al. Cemiplimab in locally
advanced cutaneous squamous cell carcinoma: results from an open-label,
phase 2, single-arm trial. Lancet Oncol
2020; 21:
294–305.31952975,
MigdenMR
KhushalaniNI
ChangALS
, et al. Cemiplimab in locally
advanced cutaneous squamous cell carcinoma: results from an open-label,
phase 2, single-arm trial. Lancet Oncol
2020; 21:
294–305.31952975
-
(
National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines®): squamous cell
skin cancer NCCN evidence blocks, version 2.2020, https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf
(2020, accessed 21 October
2020).)
National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines®): squamous cell
skin cancer NCCN evidence blocks, version 2.2020, https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf
(2020, accessed 21 October
2020).
National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines®): squamous cell
skin cancer NCCN evidence blocks, version 2.2020, https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf
(2020, accessed 21 October
2020).,
National Comprehensive Cancer Network. NCCN
Clinical Practice Guidelines in Oncology (NCCN Guidelines®): squamous cell
skin cancer NCCN evidence blocks, version 2.2020, https://www.nccn.org/professionals/physician_gls/pdf/squamous_blocks.pdf
(2020, accessed 21 October
2020).
-
Libtayo (cemiplimab-rwlc) injection, for intravenous use: highlights of prescribing information
-
A phase 2 study of REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with advanced cutaneous squamous cell carcinoma
-
(
AminMB
EdgeS
GreeneF
, et al. AJCC cancer staging
manual. 8th ed. Cham:
Springer,
2017.)
AminMB
EdgeS
GreeneF
, et al. AJCC cancer staging
manual. 8th ed. Cham:
Springer,
2017.
AminMB
EdgeS
GreeneF
, et al. AJCC cancer staging
manual. 8th ed. Cham:
Springer,
2017.,
AminMB
EdgeS
GreeneF
, et al. AJCC cancer staging
manual. 8th ed. Cham:
Springer,
2017.
-
A.
Stratigos,
C.
Garbe,
C.
Dessinioti,
C.
Lebbé,
V.
Bataille,
L.
Bastholt,
B.
Dréno,
Maria
Fargnoli,
A.
Forsea,
C.
Frenard,
C.
Harwood,
A.
Hauschild,
C.
Hoeller,
L.
Kandolf-Sekulovic,
R.
Kaufmann,
N.
Kelleners-Smeets,
J.
Malvehy,
V.
Marmol,
M.
Middleton,
D.
Moreno-Ramírez,
Giovanni
Pellecani,
K.
Peris,
P.
Saiag,
M.
Everdingen,
R.
Vieira,
I.
Zalaudek,
A.
Eggermont,
J.
Grob
(2020)
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment.
European journal of cancer
-
(
BrantschKD
MeisnerC
SchonfischB
, et al. Analysis of risk factors
determining prognosis of cutaneous squamous-cell carcinoma: a prospective
study. Lancet Oncol
2008; 9:
713–720.18617440)
BrantschKD
MeisnerC
SchonfischB
, et al. Analysis of risk factors
determining prognosis of cutaneous squamous-cell carcinoma: a prospective
study. Lancet Oncol
2008; 9:
713–720.18617440
BrantschKD
MeisnerC
SchonfischB
, et al. Analysis of risk factors
determining prognosis of cutaneous squamous-cell carcinoma: a prospective
study. Lancet Oncol
2008; 9:
713–720.18617440,
BrantschKD
MeisnerC
SchonfischB
, et al. Analysis of risk factors
determining prognosis of cutaneous squamous-cell carcinoma: a prospective
study. Lancet Oncol
2008; 9:
713–720.18617440
-
(
GrossN
FerrarottoR
NagarajanP
, et al. LBA74 – phase II study of
neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0)
cutaneous squamous cell carcinoma of the head and neck
(CSCC-HN). Ann Oncol
2019; 30: v910.)
GrossN
FerrarottoR
NagarajanP
, et al. LBA74 – phase II study of
neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0)
cutaneous squamous cell carcinoma of the head and neck
(CSCC-HN). Ann Oncol
2019; 30: v910.
GrossN
FerrarottoR
NagarajanP
, et al. LBA74 – phase II study of
neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0)
cutaneous squamous cell carcinoma of the head and neck
(CSCC-HN). Ann Oncol
2019; 30: v910.,
GrossN
FerrarottoR
NagarajanP
, et al. LBA74 – phase II study of
neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0)
cutaneous squamous cell carcinoma of the head and neck
(CSCC-HN). Ann Oncol
2019; 30: v910.
-
(
DereureO
MissanH
GirardC
, et al. Efficacy and tolerance of
cetuximab alone or combine with chemotherapy in locally advanced or
metastatic cutaneous squamous cell carcinoma: an open study of 14
patients. Dermatology
2016; 232:
721–730.28384639)
DereureO
MissanH
GirardC
, et al. Efficacy and tolerance of
cetuximab alone or combine with chemotherapy in locally advanced or
metastatic cutaneous squamous cell carcinoma: an open study of 14
patients. Dermatology
2016; 232:
721–730.28384639
DereureO
MissanH
GirardC
, et al. Efficacy and tolerance of
cetuximab alone or combine with chemotherapy in locally advanced or
metastatic cutaneous squamous cell carcinoma: an open study of 14
patients. Dermatology
2016; 232:
721–730.28384639,
DereureO
MissanH
GirardC
, et al. Efficacy and tolerance of
cetuximab alone or combine with chemotherapy in locally advanced or
metastatic cutaneous squamous cell carcinoma: an open study of 14
patients. Dermatology
2016; 232:
721–730.28384639
-
(
HillenU
LeiterU
HaaseS
, et al. Advanced cutaneous squamous
cell carcinoma: a retrospective analysis of patient profiles and treatment
patterns – results of a non-interventional study of the
DeCOG. Eur J Cancer
2018; 96:
34–43.29665511)
HillenU
LeiterU
HaaseS
, et al. Advanced cutaneous squamous
cell carcinoma: a retrospective analysis of patient profiles and treatment
patterns – results of a non-interventional study of the
DeCOG. Eur J Cancer
2018; 96:
34–43.29665511
HillenU
LeiterU
HaaseS
, et al. Advanced cutaneous squamous
cell carcinoma: a retrospective analysis of patient profiles and treatment
patterns – results of a non-interventional study of the
DeCOG. Eur J Cancer
2018; 96:
34–43.29665511,
HillenU
LeiterU
HaaseS
, et al. Advanced cutaneous squamous
cell carcinoma: a retrospective analysis of patient profiles and treatment
patterns – results of a non-interventional study of the
DeCOG. Eur J Cancer
2018; 96:
34–43.29665511
-
(
StratigosAJ
GarbeC
DessiniotiC
, et al. European interdisciplinary
guideline on invasive squamous cell carcinoma of the skin: part
2. Eur J Cancer
2020; 128:
83–102.32113942)
StratigosAJ
GarbeC
DessiniotiC
, et al. European interdisciplinary
guideline on invasive squamous cell carcinoma of the skin: part
2. Eur J Cancer
2020; 128:
83–102.32113942
StratigosAJ
GarbeC
DessiniotiC
, et al. European interdisciplinary
guideline on invasive squamous cell carcinoma of the skin: part
2. Eur J Cancer
2020; 128:
83–102.32113942,
StratigosAJ
GarbeC
DessiniotiC
, et al. European interdisciplinary
guideline on invasive squamous cell carcinoma of the skin: part
2. Eur J Cancer
2020; 128:
83–102.32113942
-
Teresa
Amaral,
M.
Osewold,
D.
Presser,
Andreas
Meiwes,
Claus
Garbe,
U.
Leiter
(2019)
Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns
Journal of the European Academy of Dermatology and Venereology, 33
-
Z.
Venables,
P.
Autier,
T.
Nijsten,
Kwok
Wong,
S.
Langan,
B.
Rous,
J.
Broggio,
C.
Harwood,
Katherine
Henson,
C.
Proby,
J.
Rashbass,
I.
Leigh
(2019)
Nationwide Incidence of Metastatic Cutaneous Squamous Cell Carcinoma in England
JAMA Dermatology, 155
-
I.
Mellman,
G.
Coukos,
G.
Dranoff
(2011)
Cancer immunotherapy comes of age
Nature, 480
-
M.
Migden,
N.
Khushalani,
A.
Chang,
K.
Lewis,
C.
Schmults,
L.
Hernandez-Aya,
F.
Meier,
D.
Schadendorf,
A.
Guminski,
A.
Hauschild,
D.
Wong,
G.
Daniels,
C.
Berking,
V.
Janković,
E.
Stankevich,
J.
Booth,
Siyu
Li,
D.
Weinreich,
G.
Yancopoulos,
I.
Lowy,
M.
Fury,
D.
Rischin
(2020)
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.
The Lancet. Oncology
-
O.
Dereure,
H.
Missan,
C.
Girard,
V.
Costes,
B.
Guillot
(2017)
Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients
Dermatology, 232
-
(
Regeneron Pharmaceuticals. A phase 2 study of
REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1), in
patients with advanced cutaneous squamous cell carcinoma
(ClinicalTrial.gov record: NCT02760498), https://clinicaltrials.gov/ct2/show/NCT02760498
(2016, accessed 27 July
2020).)
Regeneron Pharmaceuticals. A phase 2 study of
REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1), in
patients with advanced cutaneous squamous cell carcinoma
(ClinicalTrial.gov record: NCT02760498), https://clinicaltrials.gov/ct2/show/NCT02760498
(2016, accessed 27 July
2020).
Regeneron Pharmaceuticals. A phase 2 study of
REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1), in
patients with advanced cutaneous squamous cell carcinoma
(ClinicalTrial.gov record: NCT02760498), https://clinicaltrials.gov/ct2/show/NCT02760498
(2016, accessed 27 July
2020).,
Regeneron Pharmaceuticals. A phase 2 study of
REGN2810, a fully human monoclonal antibody to programmed death-1 (PD-1), in
patients with advanced cutaneous squamous cell carcinoma
(ClinicalTrial.gov record: NCT02760498), https://clinicaltrials.gov/ct2/show/NCT02760498
(2016, accessed 27 July
2020).
-
M.
Bottomley,
J.
Thomson,
C.
Harwood,
I.
Leigh
(2019)
The Role of the Immune System in Cutaneous Squamous Cell Carcinoma
International Journal of Molecular Sciences, 20
-
D.
Pfister,
K.
Ang,
D.
Brizel
(2012)
National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
-
(
AlamM
ArmstrongA
BaumC
, et al. Guidelines of care for the
management of cutaneous squamous cell carcinoma. J
Am Acad Dermatol
2018; 78:
560–578.29331386)
AlamM
ArmstrongA
BaumC
, et al. Guidelines of care for the
management of cutaneous squamous cell carcinoma. J
Am Acad Dermatol
2018; 78:
560–578.29331386
AlamM
ArmstrongA
BaumC
, et al. Guidelines of care for the
management of cutaneous squamous cell carcinoma. J
Am Acad Dermatol
2018; 78:
560–578.29331386,
AlamM
ArmstrongA
BaumC
, et al. Guidelines of care for the
management of cutaneous squamous cell carcinoma. J
Am Acad Dermatol
2018; 78:
560–578.29331386
-
(
GoodmanAM
KatoS
BazhenovaL
, et al. Tumor mutational burden as
an independent predictor of response to immunotherapy in diverse
cancers. Mol Cancer Ther
2017; 16:
2598–2608.28835386)
GoodmanAM
KatoS
BazhenovaL
, et al. Tumor mutational burden as
an independent predictor of response to immunotherapy in diverse
cancers. Mol Cancer Ther
2017; 16:
2598–2608.28835386
GoodmanAM
KatoS
BazhenovaL
, et al. Tumor mutational burden as
an independent predictor of response to immunotherapy in diverse
cancers. Mol Cancer Ther
2017; 16:
2598–2608.28835386,
GoodmanAM
KatoS
BazhenovaL
, et al. Tumor mutational burden as
an independent predictor of response to immunotherapy in diverse
cancers. Mol Cancer Ther
2017; 16:
2598–2608.28835386
-
(
BottomleyMJ
ThomsonJ
HarwoodC
, et al. The role of the immune
system in cutaneous squamous cell carcinoma. Int J
Mol Sci
2019; 20: 2009.)
BottomleyMJ
ThomsonJ
HarwoodC
, et al. The role of the immune
system in cutaneous squamous cell carcinoma. Int J
Mol Sci
2019; 20: 2009.
BottomleyMJ
ThomsonJ
HarwoodC
, et al. The role of the immune
system in cutaneous squamous cell carcinoma. Int J
Mol Sci
2019; 20: 2009.,
BottomleyMJ
ThomsonJ
HarwoodC
, et al. The role of the immune
system in cutaneous squamous cell carcinoma. Int J
Mol Sci
2019; 20: 2009.
-
Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin
-
(
MellmanI
CoukosG
DranoffG
. Cancer immunotherapy comes of
age. Nature
2011; 480:
480–489.22193102)
MellmanI
CoukosG
DranoffG
. Cancer immunotherapy comes of
age. Nature
2011; 480:
480–489.22193102
MellmanI
CoukosG
DranoffG
. Cancer immunotherapy comes of
age. Nature
2011; 480:
480–489.22193102,
MellmanI
CoukosG
DranoffG
. Cancer immunotherapy comes of
age. Nature
2011; 480:
480–489.22193102
-
(
StevensonML
WangCQ
AbikhairM
, et al. Expression of programmed
cell death ligand in cutaneous squamous cell carcinoma and treatment of
locally advanced disease with pembrolizumab. JAMA
Dermatol
2017; 153:
299–303.28259107)
StevensonML
WangCQ
AbikhairM
, et al. Expression of programmed
cell death ligand in cutaneous squamous cell carcinoma and treatment of
locally advanced disease with pembrolizumab. JAMA
Dermatol
2017; 153:
299–303.28259107
StevensonML
WangCQ
AbikhairM
, et al. Expression of programmed
cell death ligand in cutaneous squamous cell carcinoma and treatment of
locally advanced disease with pembrolizumab. JAMA
Dermatol
2017; 153:
299–303.28259107,
StevensonML
WangCQ
AbikhairM
, et al. Expression of programmed
cell death ligand in cutaneous squamous cell carcinoma and treatment of
locally advanced disease with pembrolizumab. JAMA
Dermatol
2017; 153:
299–303.28259107
-
(
NelsonTG
AshtonRE
. Low incidence of metastasis and recurrence from
cutaneous squamous cell carcinoma found in a UK population: do we need to
adjust our thinking on this rare but potentially fatal
event?
J Surg Oncol
2017; 116:
783–788.28703911)
NelsonTG
AshtonRE
. Low incidence of metastasis and recurrence from
cutaneous squamous cell carcinoma found in a UK population: do we need to
adjust our thinking on this rare but potentially fatal
event?
J Surg Oncol
2017; 116:
783–788.28703911
NelsonTG
AshtonRE
. Low incidence of metastasis and recurrence from
cutaneous squamous cell carcinoma found in a UK population: do we need to
adjust our thinking on this rare but potentially fatal
event?
J Surg Oncol
2017; 116:
783–788.28703911,
NelsonTG
AshtonRE
. Low incidence of metastasis and recurrence from
cutaneous squamous cell carcinoma found in a UK population: do we need to
adjust our thinking on this rare but potentially fatal
event?
J Surg Oncol
2017; 116:
783–788.28703911
-
(
JarkowskiA3rd
HareR
LoudP
, et al. Systemic therapy in advanced
cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a
review of the literature. Am J Clin Oncol
2016; 39:
545–548.24879468)
JarkowskiA3rd
HareR
LoudP
, et al. Systemic therapy in advanced
cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a
review of the literature. Am J Clin Oncol
2016; 39:
545–548.24879468
JarkowskiA3rd
HareR
LoudP
, et al. Systemic therapy in advanced
cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a
review of the literature. Am J Clin Oncol
2016; 39:
545–548.24879468,
JarkowskiA3rd
HareR
LoudP
, et al. Systemic therapy in advanced
cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a
review of the literature. Am J Clin Oncol
2016; 39:
545–548.24879468
-
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: part 2
-
(
Skin tumours. In:
BrierleyJD
GospodarowiczMK
EittekindC
(eds) TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
John Wiley & Sons Inc.,
2017, pp.
131–149.)
Skin tumours. In:
BrierleyJD
GospodarowiczMK
EittekindC
(eds) TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
John Wiley & Sons Inc.,
2017, pp.
131–149.
Skin tumours. In:
BrierleyJD
GospodarowiczMK
EittekindC
(eds) TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
John Wiley & Sons Inc.,
2017, pp.
131–149.,
Skin tumours. In:
BrierleyJD
GospodarowiczMK
EittekindC
(eds) TNM classification of malignant tumours.
8th ed. Hoboken, NJ:
John Wiley & Sons Inc.,
2017, pp.
131–149.
-
(
LeeA
DugganS
DeeksED
. Cemiplimab: a review in advanced cutaneous
squamous cell carcinoma. Drugs
2020; 80:
813–819.32306208)
LeeA
DugganS
DeeksED
. Cemiplimab: a review in advanced cutaneous
squamous cell carcinoma. Drugs
2020; 80:
813–819.32306208
LeeA
DugganS
DeeksED
. Cemiplimab: a review in advanced cutaneous
squamous cell carcinoma. Drugs
2020; 80:
813–819.32306208,
LeeA
DugganS
DeeksED
. Cemiplimab: a review in advanced cutaneous
squamous cell carcinoma. Drugs
2020; 80:
813–819.32306208
-
Arnold
Lee,
S.
Duggan,
E.
Deeks
(2020)
Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma
Drugs, 80
-
(
TopalianSL
DrakeCG
PardollDM.
Immune checkpoint blockade: a common denominator approach to
cancer therapy. Cancer Cell
2015; 27:
450–461.25858804)
TopalianSL
DrakeCG
PardollDM.
Immune checkpoint blockade: a common denominator approach to
cancer therapy. Cancer Cell
2015; 27:
450–461.25858804
TopalianSL
DrakeCG
PardollDM.
Immune checkpoint blockade: a common denominator approach to
cancer therapy. Cancer Cell
2015; 27:
450–461.25858804,
TopalianSL
DrakeCG
PardollDM.
Immune checkpoint blockade: a common denominator approach to
cancer therapy. Cancer Cell
2015; 27:
450–461.25858804
-
Libtayo (cemiplimab): EPAR -product information
-
E.
Soura,
E.
Gagari,
A.
Stratigos
(2019)
Advanced cutaneous squamous cell carcinoma: how is it defined and what new therapeutic approaches are available?
Current Opinion in Oncology
-
Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma. Technology appraisal guidance [TA592]
-
(
SchmultsCD
KariaPS
CarterJB
, et al. Factors predictive of
recurrence and death from cutaneous squamous cell carcinoma: a 10-year,
single-institution cohort study. JAMA
Dermatol
2013; 149:
541–547.23677079)
SchmultsCD
KariaPS
CarterJB
, et al. Factors predictive of
recurrence and death from cutaneous squamous cell carcinoma: a 10-year,
single-institution cohort study. JAMA
Dermatol
2013; 149:
541–547.23677079
SchmultsCD
KariaPS
CarterJB
, et al. Factors predictive of
recurrence and death from cutaneous squamous cell carcinoma: a 10-year,
single-institution cohort study. JAMA
Dermatol
2013; 149:
541–547.23677079,
SchmultsCD
KariaPS
CarterJB
, et al. Factors predictive of
recurrence and death from cutaneous squamous cell carcinoma: a 10-year,
single-institution cohort study. JAMA
Dermatol
2013; 149:
541–547.23677079
-
(
MaubecE
PetrowP
Scheer-SenyarichI
, et al. Phase II study of cetuximab
as first-line single-drug therapy in patients with unresectable squamous
cell carcinoma of the skin. J Clin Oncol
2011; 29:
3419–3426.21810686)
MaubecE
PetrowP
Scheer-SenyarichI
, et al. Phase II study of cetuximab
as first-line single-drug therapy in patients with unresectable squamous
cell carcinoma of the skin. J Clin Oncol
2011; 29:
3419–3426.21810686
MaubecE
PetrowP
Scheer-SenyarichI
, et al. Phase II study of cetuximab
as first-line single-drug therapy in patients with unresectable squamous
cell carcinoma of the skin. J Clin Oncol
2011; 29:
3419–3426.21810686,
MaubecE
PetrowP
Scheer-SenyarichI
, et al. Phase II study of cetuximab
as first-line single-drug therapy in patients with unresectable squamous
cell carcinoma of the skin. J Clin Oncol
2011; 29:
3419–3426.21810686
-
(
SamsteinRM
LeeCH
ShoushtariAN
, et al. Tumor mutational load
predicts survival after immunotherapy across multiple cancer
types. Nat Genet
2019; 51:
202–206.30643254)
SamsteinRM
LeeCH
ShoushtariAN
, et al. Tumor mutational load
predicts survival after immunotherapy across multiple cancer
types. Nat Genet
2019; 51:
202–206.30643254
SamsteinRM
LeeCH
ShoushtariAN
, et al. Tumor mutational load
predicts survival after immunotherapy across multiple cancer
types. Nat Genet
2019; 51:
202–206.30643254,
SamsteinRM
LeeCH
ShoushtariAN
, et al. Tumor mutational load
predicts survival after immunotherapy across multiple cancer
types. Nat Genet
2019; 51:
202–206.30643254
-
A.
Thompson,
B.
Kelley,
L.
Prokop,
M.
Murad,
C.
Baum
(2016)
Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis.
JAMA dermatology, 152 4
-
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): squamous cell skin cancer, version 2.2021
-
(
PerisK
AlaibacM
ArgenzianoG
, et al. Cutaneous squamous cell
carcinoma. Italian guidelines by SIDeMaST adapted to and updating
EADO/EDF/EORTC guidelines. G Ital Dermatol
Venereol
2018; 153:
747–762.29898593)
PerisK
AlaibacM
ArgenzianoG
, et al. Cutaneous squamous cell
carcinoma. Italian guidelines by SIDeMaST adapted to and updating
EADO/EDF/EORTC guidelines. G Ital Dermatol
Venereol
2018; 153:
747–762.29898593
PerisK
AlaibacM
ArgenzianoG
, et al. Cutaneous squamous cell
carcinoma. Italian guidelines by SIDeMaST adapted to and updating
EADO/EDF/EORTC guidelines. G Ital Dermatol
Venereol
2018; 153:
747–762.29898593,
PerisK
AlaibacM
ArgenzianoG
, et al. Cutaneous squamous cell
carcinoma. Italian guidelines by SIDeMaST adapted to and updating
EADO/EDF/EORTC guidelines. G Ital Dermatol
Venereol
2018; 153:
747–762.29898593